Diabetes: HbA1c Poor Control (NQF 0059)

Similar documents
Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)

Weight Assessment and Counseling for Children and Adolescents (NQF 0024)

Childhood Immunization Status (NQF 0038)

Childhood Immunization Status (NQF 0038)

2017 CMS Web Interface

2018 CMS Web Interface

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache

Swindon Joint Strategic Needs Assessment Bulletin

High Performance Network Quality Criteria for Designation

Obesity/Morbid Obesity/BMI

2017 CMS Web Interface

2017 CMS Web Interface

2017 CMS Web Interface

CONTACT: Amber Hamilton TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW

2018 CMS Web Interface

2018 CMS Web Interface

2018 CMS Web Interface

2017 CMS Web Interface

2018 CMS Web Interface

Michigan Primary Care Transformation Project Performance Incentive Technical Manual

2018 CMS Web Interface

LTCH QUALITY REPORTING PROGRAM

Measure Information Form

Commissioning Policy: South Warwickshire CCG (SWCCG)

CLINICAL MEDICAL POLICY

2017 CMS Web Interface

Osteoporosis Fast Facts

2018 CMS Web Interface

2018 CMS Web Interface

The principles of evidence-based medicine

Pain Management Learning Plan

BRCA1 and BRCA2 Mutations

Pennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain

Policy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid

Echocardiography Diagnostic Accuracy

CDC Influenza Technical Key Points February 15, 2018

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.

Solid Organ Transplant Benefits to Change for Texas Medicaid

Related Policies None

Diabetes Mellitus Lab Tests (Screening, Diagnosis & Monitoring)

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

2017 CMS Web Interface

CDC Influenza Division Key Points MMWR Updates February 20, 2014

CONSENT FORM - TESTOSTERONE FOR TRANSGENDER CLIENTS

Chapter 6: Impact Indicators

Diabetes Canada Pre-Budget Consultation Submission. Standing Committee on Finance and Economic Affairs. Government of Ontario.

ICD-10-CM Coding Basics Chapter Specifics

Risk factors in health and disease

Cardiac Rehabilitation Services

Meaningful Use Roadmap Stage Edition Eligible Hospitals

2018 Medical Association Poster Symposium Guidelines

Referral Criteria: Inflammation of the Spine Feb

Trust Guideline for Urgent Brain Imaging and Management of Suspected Subarachnoid Haemorrhage

Ontario 2018 provincial election issues backgrounder

Frequently Asked Questions: IS RT-Q-PCR Testing

ACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals.

OTHER AND UNSPECIFIED DISORDERS

Implementation of G6PD testing and radical cure in P. vivax endemic countries: considerations

Do Not Cite. Draft for Work Group Review.

o Procedures performed o Diagnoses Identified o Certain devices/equipment/supplies acquired for patient

Topic 12: Endocrine System. Function: Group of glands that produces regulatory chemicals ( )

Commonwealth of Kentucky Department for Medicaid Services Division of Program Quality and Outcomes

Cancer Association of South Africa (CANSA)

MGPR Training Courses Guide

COPD Outreach Program

Completing the NPA online Patient Safety Incident Report form: 2016

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

Year 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:

Male patients with pain, swelling or erythema please refer to the Acute Painful Scrotum pathway Female patients

Patterns of Cholesterol Distribution in the Participants of a Screening Project

2013 DATA COLLECTION GUIDE Summary Data Submission. Optimal Asthma Care. (07/01/2012 to 06/30/2013 Dates of Service)

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers

Hospital Preparedness Checklist

UNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES.

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers

INTRAVENOUS FLUID THERAPY CLINICAL CARE RECOMMENDATIONS

Waterloo Wellington Rehabilitative Care System Integrated Care Pathway for STROKE Stream of Care HYPERACUTE URGENT TIA and SECONDARY STROKE PREVENTION

Pediatric and adolescent preventive care and HEDIS *

2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE

Frontier School of Innovation District Wellness Policy

Human papillomavirus (HPV) refers to a group of more than 150 related viruses.

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST

Hospital Performance Series

Physical Fitness for the Physically Limited. o Work Experience, General. o Open Entry/Exit. Distance (Hybrid Online) for online supported courses

Statement of Work for Linked Data Consulting Services

2018 CMS Web Interface

Public consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking

TITLE: Managing Menopausal Symptoms in Breast Cancer Survivors

Reliability and Validity Plan 2017

Ancillary Symposia Request for Proposals Partner with the Endocrine Society to Educatte the Endocrine Community.

TELCOMMUNICATIONS CONSUMER PROTECTIONS CODE (C628:2012) EXPLANATORY STATEMENT

QUALITY AND SAFETY MEASURES UPDATE January 2016

Transcription:

Diabetes: HbA1c Pr Cntrl (NQF 0059) EMeasure Name Diabetes: HbA1c Pr Cntrl EMeasure Id Pending Versin Number 1 Set Id Pending Available Date N infrmatin Measurement January 1, 20xx thrugh Perid December 31, 20xx Measure Steward Natinal Cmmittee fr Quality Assurance Endrsed by Natinal Quality Frum Descriptin The percentage f patients 18 75 years f age with diabetes (type 1 r type 2) wh had HbA1c >9.0%. Measure scring Prprtin Measure type Prcess Ratinale This measure assesses the percentage f patients in a specific age demgraphic wh were diagnsed with type 1 r type 2 diabetes and wh demnstrate pr bld sugar cntrl with an HbA1c level higher than 9 percent. Diabetes mellitus (diabetes) is a grup f diseases characterized by high bld glucse levels caused by the bdy s inability t crrectly prduce r utilize the hrmne insulin. It is recgnized as a leading cause f death and disability in the U.S. and is highly underreprted as a cause f death. Diabetes f either type may cause lifethreatening, life ending r life altering cmplicatins, including pr bld sugar cntrl. Studies have shwn that imprved glycemic cntrl is crrelated with a 40%decline in the develpment f assciated micrvascular cmplicatins (i.e., eye, kidney and nerve diseases) (ADA 2009). Clinical guidelines recmmend regular HbA1c testing t facilitate patients ability t imprve and sustain acceptable levels (ADA 2009). This measure facilitates the preventin and lngterm management f high bld sugar levels fr patients diagnsed with diabetes. Clinical American Geriatric Sciety Recmmendatin Statement Fr frail lder adults, persns with life expectancy f less than 5 years, and thers in whm the risks f intensive glycemic cntrl appear t utweigh the benefits, a less stringent target such as 8% is apprpriate. (Level III, Grade B) Fr lder persns, target hemglbin A1C shuld be individualized. A reasnable gal fr A1C in relatively healthy adults with gd functinal status is 7% r lwer. (Level III, Grade B) American Diabetes Assciatin Lwering A1C t belw r arund 7% has been shwn t reduce micrvascular and neurpathic cmplicatins f type 1 and type 2 diabetes. Therefre, fr micrvascular disease preventin, the A1C gal fr nnpregnant adults in general is <7%. (A) References Standards f Medical Care in Diabetes 2009. Diabetes Care January 2009 32:S6 S12; di:10.2337/dc09 S006

Definitins Guidelines fr Imprving the Care f the Older Persn with Diabetes Mellitus. Califrnia Healthcare Fundatin/American Geriatrics Sciety Panel n Imprving Care fr Elders with Diabetes. American Geriatrics Sciety. May 2003 Vl. 51, N. 5 Supplement. JAGS. Table f Cntents Ppulatin criteria Data criteria (QDS Data Elements) Summary calculatin Please refer t the spreadsheet fr this measure fr detail regarding data criteria and cde lists. Ppulatin criteria Initial Patient Ppulatin = AND: Patient characteristic: birth date (age) > =17 years and <=74 years t capture all patients wh will reach the ages between 18 and 75 years during the measurement perid ; Denminatr = AND: All patients in the initial patient ppulatin; AND: OR: Medicatin dispensed: medicatins indicative f diabetes <=2 years befre r simultaneusly t OR: Medicatin rder: medicatins indicative f diabetes <=2 years befre r simultaneusly t OR: Medicatin active: medicatins indicative f diabetes <=2 years befre r simultaneusly t OR: Diagnsis active: diabetes <=2 years befre r simultaneusly t OR: >=1 cunt(s) f Encunter: encunter acute inpatient r ED ; OR: >=2 cunt(s) f Encunter: encunter nn acute inpt, utpatient, r phthalmlgy ccurring n 2 different dates;

Numeratr = AND: Labratry test result: HbA1c test, MOST RECENT value > 9.0%; Exclusins = OR: Diagnsis active: plycystic varies ; AND NOT: Diagnsis active: diabetes <= 2 years befre r simultaneusly t OR: Encunter: encunter acute inpatient r ED <=2 years befre r simultaneusly t OR: Encunter: encunter nn acute inpt, utpatient, r phthalmlgy <=2 years befre r simultaneusly t OR: AND NOT: OR: Diagnsis active: gestatinal diabetes <=2 years befre r simultaneusly t OR: Diagnsis active: sterid induced diabetes <=2 years befre r simultaneusly t OR: Medicatin rder: medicatins indicative f diabetes <=2 years befre r simultaneusly t OR: Medicatin dispensed: medicatins indicative f diabetes <=2 years befre r simultaneusly t OR: Medicatin active: medicatins indicative f diabetes <=2 years befre r simultaneusly t Diagnsis active: diabetes <=2 years befre r simultaneusly t OR: Encunter: Encunter acute inpatient r ED <=2 years befre r simultaneusly t

OR: Encunter: encunter nn acute inpt, utpatient, r phthalmlgy <=2 years befre r simultaneusly t Data criteria (QDS Data Elements) Initial Patient Ppulatin = Patient characteristic: birth date using birth date cde list befre the measurement perid ; Denminatr = Diagnsis active: diabetes using diabetes cde list gruping befre r simultaneusly t the Encunter: encunter acute inpatient r ED using encunter acute inpatient r ED cde list gruping during the measurement perid ; Encunter: encunter nn acute inpt, utpatient, r phthalmlgy using encunter nn acute inpt, utpatient, r phthalmlgy cde list gruping during the measurement perid ; Medicatin rder: medicatins indicative f diabetes using medicatins indicative f diabetes cde list gruping befre r simultaneusly t the Medicatin dispensed: medicatins indicative f diabetes using medicatins indicative f diabetes cde list gruping befre r simultaneusly t the measurement end date ; Medicatin active: medicatins indicative f diabetes using medicatins indicative f diabetes cde list gruping befre r simultaneusly t the Numeratr = Labratry test result: HbA1c test using HbA1c test cde list gruping during the measurement perid ; Exclusins = Diagnsis active: plycystic varies using plycystic varies cde list gruping befre r simultaneusly t the Diagnsis active: gestatinal diabetes using gestatinal diabetes cde list gruping befre r simultaneusly t the Diagnsis active: sterid induced diabetes using sterid induced diabetes cde list gruping befre r simultaneusly t the Summary calculatin Calculatin is generic t all measures: Calculate the final denminatr by adding all that meet denminatr criteria. Subtract frm the final denminatr all that d nt meet numeratr criteria yet als meet exclusin criteria. Nte sme measures d nt have exclusin criteria.

The perfrmance calculatin is the number meeting numeratr criteria divided by the final denminatr. Fr measures with multiple patient ppulatins, repeat this prcess fr each patient ppulatin and reprt each result separately. Fr measures with multiple numeratrs, calculate each numeratr separately within each ppulatin using the paired exclusin. Measure set CLINICAL QUALITY MEASURE SET 2011 2012